JP2016513113A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513113A5 JP2016513113A5 JP2015558212A JP2015558212A JP2016513113A5 JP 2016513113 A5 JP2016513113 A5 JP 2016513113A5 JP 2015558212 A JP2015558212 A JP 2015558212A JP 2015558212 A JP2015558212 A JP 2015558212A JP 2016513113 A5 JP2016513113 A5 JP 2016513113A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- alkyl
- aryl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 14
- 239000012646 vaccine adjuvant Substances 0.000 claims description 14
- 229940124931 vaccine adjuvant Drugs 0.000 claims description 14
- 108091034117 Oligonucleotide Proteins 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000000069 prophylactic effect Effects 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 4
- 229930024421 Adenine Natural products 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 229960000643 adenine Drugs 0.000 claims description 4
- 229940104302 cytosine Drugs 0.000 claims description 4
- 239000001177 diphosphate Substances 0.000 claims description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 4
- 235000011180 diphosphates Nutrition 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 150000004712 monophosphates Chemical class 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- 229940113082 thymine Drugs 0.000 claims description 4
- 229940035893 uracil Drugs 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000001226 triphosphate Substances 0.000 claims 2
- 235000011178 triphosphate Nutrition 0.000 claims 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 description 28
- 0 CC(C)OC(OCSP(O)(OCC(O[C@](C1)[n]2c(ncnc3N)c3nc2)=C1O)OC(C1OC)=C(C*)O[C@]1N(C=CC(N1)=O)C1=O)=O Chemical compound CC(C)OC(OCSP(O)(OCC(O[C@](C1)[n]2c(ncnc3N)c3nc2)=C1O)OC(C1OC)=C(C*)O[C@]1N(C=CC(N1)=O)C1=O)=O 0.000 description 3
- -1 racemates Chemical class 0.000 description 3
- 230000008076 immune mechanism Effects 0.000 description 2
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- AQIUHCXCZZBYDB-UBFDHDLASA-N CC(C)OC(OCSP(OCC(OCC1CN2C=NC3C(N)=NC=NC23)=C1O)(OC(CCO)(CO[C@H]1N(C=CC(N2)=O)C2=O)C1OC)=O)=O Chemical compound CC(C)OC(OCSP(OCC(OCC1CN2C=NC3C(N)=NC=NC23)=C1O)(OC(CCO)(CO[C@H]1N(C=CC(N2)=O)C2=O)C1OC)=O)=O AQIUHCXCZZBYDB-UBFDHDLASA-N 0.000 description 1
- FOIAGHYDGKPKBC-HDXGMXLUSA-N CCN(C(C)(CCO)OC(COP(OC(C1OC)=C(CO)O[C@H]1N(C=CC(N1)=O)C1=O)(S)=O)=C)c(ncnc1N)c1N Chemical compound CCN(C(C)(CCO)OC(COP(OC(C1OC)=C(CO)O[C@H]1N(C=CC(N1)=O)C1=O)(S)=O)=C)c(ncnc1N)c1N FOIAGHYDGKPKBC-HDXGMXLUSA-N 0.000 description 1
- UQKPBVRTZIOAOZ-HTXNQAPBSA-N CCO/C(/COP(Oc1c(CO)[o]c(N(C(C)N2)C=CC2=O)c1OC)(SCOC(OC(C)C)=O)=O)=C(\CCN(c(ncnc1N)c1N)O)/O Chemical compound CCO/C(/COP(Oc1c(CO)[o]c(N(C(C)N2)C=CC2=O)c1OC)(SCOC(OC(C)C)=O)=O)=C(\CCN(c(ncnc1N)c1N)O)/O UQKPBVRTZIOAOZ-HTXNQAPBSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766011P | 2013-02-18 | 2013-02-18 | |
| US61/766,011 | 2013-02-18 | ||
| PCT/US2014/016996 WO2014127378A2 (en) | 2013-02-18 | 2014-02-18 | Design of short oligonucleotides as vaccine adjuvants and therapeutic agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018031870A Division JP2018087243A (ja) | 2013-02-18 | 2018-02-26 | ワクチンアジュバントおよび治療剤としての短鎖オリゴヌクレオチドの設計 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513113A JP2016513113A (ja) | 2016-05-12 |
| JP2016513113A5 true JP2016513113A5 (enExample) | 2017-03-23 |
| JP6502267B2 JP6502267B2 (ja) | 2019-04-17 |
Family
ID=51354704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558212A Expired - Fee Related JP6502267B2 (ja) | 2013-02-18 | 2014-02-18 | ワクチンアジュバントおよび治療剤としての短鎖オリゴヌクレオチドの設計 |
| JP2018031870A Withdrawn JP2018087243A (ja) | 2013-02-18 | 2018-02-26 | ワクチンアジュバントおよび治療剤としての短鎖オリゴヌクレオチドの設計 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018031870A Withdrawn JP2018087243A (ja) | 2013-02-18 | 2018-02-26 | ワクチンアジュバントおよび治療剤としての短鎖オリゴヌクレオチドの設計 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10391166B2 (enExample) |
| EP (1) | EP2956145A4 (enExample) |
| JP (2) | JP6502267B2 (enExample) |
| KR (1) | KR20150119924A (enExample) |
| CN (1) | CN105992587A (enExample) |
| AU (1) | AU2014217892B2 (enExample) |
| CA (1) | CA2899599A1 (enExample) |
| WO (1) | WO2014127378A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2991156A1 (en) * | 2015-07-02 | 2017-01-05 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of viral infection |
| TW201717968A (zh) * | 2015-07-14 | 2017-06-01 | 春季銀行製藥公司 | 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物 |
| WO2018013887A1 (en) * | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| KR20190039522A (ko) * | 2016-07-15 | 2019-04-12 | 스페로비 바이오사이언시즈 인코포레이티드 | 질병 치료를 위한 화합물, 조성물 및 방법 |
| WO2019046511A1 (en) * | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
| CA3072766A1 (en) * | 2017-09-05 | 2019-03-14 | Blackthorn Therapeutics, Inc. | 2,6-diazaspiro[3.3]hepatan-2-yl derivatives and pharmaceutical compostions thereof useful as vasopressin receptor antagonists |
| WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| WO2019051489A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
| MX2020011733A (es) * | 2018-05-04 | 2021-01-15 | Ubi Ip Holdings | Epítopos de células t cooperadoras promiscuos artificiales que facilitan la producción de anticuerpos diana con respuesta inflamatoria de células t limitada. |
| WO2021040439A1 (ko) * | 2019-08-28 | 2021-03-04 | 주식회사 엔에이백신연구소 | 신규한 핵산을 기반으로 하는 인플루엔자 백신 조성물 |
| WO2021046426A1 (en) * | 2019-09-06 | 2021-03-11 | Sperovie Biosciences, Inc. | Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8076303B2 (en) * | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
| US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| WO2009146123A2 (en) * | 2008-04-03 | 2009-12-03 | Spring Bank | Compositions and methods for treating viral infections |
| EP2611451A4 (en) * | 2010-08-30 | 2014-01-15 | Spring Bank Pharmaceuticals Inc | DESIGN OF OLIGONUCLEOTIDE ANALOGUES AS THERAPEUTIC AGENTS |
-
2014
- 2014-02-18 CA CA2899599A patent/CA2899599A1/en not_active Abandoned
- 2014-02-18 CN CN201480009224.7A patent/CN105992587A/zh active Pending
- 2014-02-18 WO PCT/US2014/016996 patent/WO2014127378A2/en not_active Ceased
- 2014-02-18 US US14/767,113 patent/US10391166B2/en not_active Expired - Fee Related
- 2014-02-18 KR KR1020157025458A patent/KR20150119924A/ko not_active Withdrawn
- 2014-02-18 JP JP2015558212A patent/JP6502267B2/ja not_active Expired - Fee Related
- 2014-02-18 EP EP14750982.2A patent/EP2956145A4/en not_active Withdrawn
- 2014-02-18 AU AU2014217892A patent/AU2014217892B2/en not_active Ceased
-
2018
- 2018-02-26 JP JP2018031870A patent/JP2018087243A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513113A5 (enExample) | ||
| EA202190602A3 (ru) | 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний | |
| MD20220043A2 (ro) | Compuşi foarte activi împotriva COVID-19 | |
| JP2020503009A5 (enExample) | ||
| JP2019501133A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2017531038A5 (enExample) | ||
| JP2018199694A5 (enExample) | ||
| JP2020503010A5 (enExample) | ||
| JP2016508134A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| GT200500221A (es) | Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan. | |
| WO2016096174A8 (en) | Cyclic dinucleotides for cytokine induction | |
| JP2018509409A5 (enExample) | ||
| JP2015024998A5 (enExample) | ||
| EA201170915A1 (ru) | Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций | |
| WO2008100447A3 (en) | Nucleoside analogs for antiviral treatment | |
| JP2016525102A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2013541514A5 (enExample) | ||
| HRP20171808T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova uporaba za liječenje hiv infekcija | |
| JP2019500387A5 (enExample) | ||
| JP2015517555A5 (enExample) | ||
| GEP20237502B (en) | B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |